Taha Merghoub

Taha Merghoub serves as Deputy Director of the Meyer Cancer Center and Professor of Pharmacology and Immunology Research in Medicine at Weill Cornell Medicine (WCM), holding the Margaret and Herman Sokol Professorship of Oncology Research. His laboratory pioneers research on tumor resistance mechanisms to immune-based therapies, with translational focus on melanoma, lung, breast, and bladder cancers.

His educational background includes:

• BA: University of Algiers, Algeria
• MS and PhD (highest distinction): University of Paris, France

Dr. Merghoub's research centers on tumor immunology and immunotherapy resistance, with key emphases on:

• Myeloid-derived suppressor cells and regulatory T cell dynamics
• Tumor metabolism (glycolysis, tryptophan catabolism) in immune evasion
• Neutrophil-mediated elimination of antigen escape variants
• Combination strategies (checkpoint blockade, chemotherapy, targeted therapy)
• CAR T-cell engineering for solid tumors

Analysis of his publication record reveals consistent breakthroughs in understanding the tumor microenvironment's role in therapy resistance, with recent work highlighting metabolic vulnerabilities and novel immune cell interactions across multiple cancer types.

His scientific distinctions include:

• Margaret and Herman Sokol Professor of Oncology Research
• Top 2% most cited researcher worldwide (h-index 75, 35,830+ citations)
• Leadership of the Meyer Cancer Center

Dr. Merghoub directs highly collaborative research initiatives supported by:

• Ludwig Collaborative Laboratory funding
• Swim Across America Laboratory program
• Tri-institutional partnerships with Memorial Sloan Kettering

He maintains an active tissue repository for immunotherapy research and leads interdisciplinary teams developing translational cancer therapies through the Meyer Cancer Center infrastructure.